Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Down 3.3% – Time to Sell?

Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) were down 3.3% on Tuesday . The company traded as low as $1.47 and last traded at $1.48. Approximately 39,089 shares traded hands during trading, a decline of 19% from the average daily volume of 48,092 shares. The stock had previously closed at $1.53.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Trading Down 4.6%

The stock’s 50-day moving average price is $2.34 and its 200-day moving average price is $3.90. The company has a market capitalization of $3.70 million, a P/E ratio of -0.17 and a beta of -1.16.

Institutional Trading of Acurx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new position in Acurx Pharmaceuticals during the 2nd quarter valued at approximately $551,000. O Brien Greene & Co. Inc acquired a new stake in Acurx Pharmaceuticals in the second quarter worth $31,000. Millennium Management LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter valued at $103,000. Geode Capital Management LLC acquired a new position in shares of Acurx Pharmaceuticals during the fourth quarter valued at $31,000. Finally, Jane Street Group LLC bought a new position in shares of Acurx Pharmaceuticals during the fourth quarter worth about $27,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).